Drug recall · September 14, 2016
Ondansetron Injection USP 40 mg/20 mL recall
Why: CGMP Deviations
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Ondansetron Injection USP 40 mg/20 mL (2 mg/mL), Rx Only, Manufactured in Hungary for TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454 NDC # 0703-7226-01 (20 mL- Multi-dose Vial), NDC # 0703-72263-03 (10 Multi-dose Vials per carton)
- Lots / codes
All Lots Within Expiry Lot # 2930614, 2940614, 2950614
- Quantity
- 13,223 vials
- Company
- Teva North America, Horsham, PA
- Distribution
- Nationwide and Puerto Rico
- Initiated
- June 17, 2016 · Voluntary: Firm initiated
- Classified
- September 7, 2016
- Reported
- September 14, 2016
- Ended
- February 7, 2017
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Ondansetron
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.